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Cytokine-Facilitated Transduction Leads to Low-Level Engraftment
in Nonablated Hosts
By Ellen L.W. Kittler, Stefan O. Peters, Rowena B. Crittenden, Michelle E. Debatis, Hayley S. Ramshaw,
F. Marc Stewart, and Peter J. Quesenberry
Using a murine bone marrow transplantation model, we However, polymerase chain reaction amplification of DNAs
from bone marrow, spleen, and peripheral blood showed noevaluated the long-term engraftment of retrovirally trans-
duced bone marrow cells in nonmyeloablated hosts. Male evidence of the transduced MDR1 gene. RT-PCR analysis of
total bone marrow RNA showed that transcripts from thebone marrow was stimulated in a cocktail of interleukin-3
(IL-3), IL-6, IL-11, and stem cell factor (SCF) for 48 hours, MDR1 gene were present in a fraction of the engrafted donor
cells. These data show functional transfer of the MDR1 genethen cocultured on the retroviral producer line MDR18.1 for
an additional 24 hours. Functional transduction of hemato- into nonmyeloablated murine hosts. However, the high
rates of in vitro transduction into HPP-CFC, coupled with thepoietic progenitors was detected in vitro by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) amplification low in vivo engraftment rate of donor cells containing the
MDR1 gene, suggest that the majority of stem cells thatof multiple drug resistance 1 (MDR1) mRNA from high prolif-
erative potential-colony forming cell (HPP-CFC) colonies. incorporated the retroviral construct did not stably engraft
in the host. Based on additional studies that indicate that exAfter retroviral transduction, male bone marrow cells were
injected into nonablated female mice. Transplant recipients vivo culture of bone marrow induces an engraftment defect
concomitantly with progression of cells through S phase,received three TAXOL (Bristol-Myers, Princeton, NJ) injec-
tions (10 mg/kg) over a 14-month period. Transplant recipi- we propose that the cell cycle transit required for proviral
integration reduces or impairs the ability of transduced cellsent tissues were analyzed by Southern blot and fluorescence
in situ hybridization for Y-chromosome–specific sequences to stably engraft.
q 1997 by The American Society of Hematology.and showed donor cell engraftment of approximately 9%.
H ceiving 5FU-treated transduced cells25,26 indicates that inte-gration occurs in a very early progenitor. The expression ofEMATOPOIETIC PROGENITOR cells, because oftheir renewal capacity as well as multilineage contri-
bution, are an ideal target for the delivery of gene therapy MDR1 in cells of the hematopoietic lineages should provide
host resistance to a variety of chemotherapuetic agents. Thisfor both disease treatment and genetic ‘‘rescue.’’1-3 Gene
transfer into hematopoietic cells by retroviral transduction protects the marrow cells from the effects of the drugs and
may allow safe delivery of greater therapeutic doses. Overex-has proven partially successful giving low-level and often
short-term expression of the transduced genes both in human pression of the MDR1 gene, along with another therapeutic
agent in a dicistronic vector would also permit the positiveand animal models. The delivery of hematopoietic progenitor
cells transfected with a foreign gene into myeloablated hosts, selection of progenitor cells in vitro or in vivo, which may
be of special benefit when transplanting transduced cells intowhich received either substantial chemotherapy or irradia-
tion, leads to marrow reconstitution and variable degrees of a normal host.
In this report, using an MDR1 retroviral vector, we showgene expression.4-18
The capacity of hematopoietic progenitor cells to lead to a high rate of successful transduction of primitive hemato-
poietic cells in vitro by mRNA expression of the MDR1substantial engraftment in normal nonmyeloablated hosts,
gives rise to reasonable expectation that transduced progeni- transgene in hematopoietic progenitor cell-derived colonies
(multifactor responsive high proliferative potential-colonytor cells may be capable of delivering new gene sequences
in a clinical or therapeutic situation where transplant without forming cells [HPP-CFCs]). Additionally, we confirm the
ability of transduced progenitor cells to engraft into the nor-myeloablation is desirable, such as in the case of genetic
diseases or human immunodeficiency virus (HIV). A murine mal, nonmyeloablated host.
transplant model, which shows reproducible engraftment ki-
MATERIALS AND METHODSnetics for normal bone marrow, has been well characterized
and used extensively to establish the nature of the long- Bone marrow harvest. Bone marrow was harvested from the
tibia and femur of male BALB/c mice (18-22 g, Charles River,term repopulating progenitor cells.19-22 The ability to deliver
progenitor cells into a normal host provides the opportunity
to assess the potential of transduced (retrovirally transfected) From the University of Massachusetts Cancer Center, Worcester,
progenitor cells to engraft in the nonmyeloablated environ- MA.
Submitted March 1, 1995; accepted March 11, 1997.ment. The therapeutic potential for delivery of genes to a
Supported by research grants from the National Institutes ofnonablated host is relevant to gene therapy applications, and
Health (#PO1.CA27466), the American Cancer Society (#DHP-96),transferring a selectable marker would offer operational and
and the University of Massachusetts Medical Center.therapeutic advantages.
Address reprint requests to Ellen L.W. Kittler, PhD, UniversityThe human MDR1 multiple drug resistance 1 (MDR1)
of Massachusetts Cancer Center, Two Biotech, 373 Plantationgene produces a membrane protein that confers resistance Street, Suite 207, Worcester, MA 01605.
to p170 pumped drugs in a variety of cell types including The publication costs of this article were defrayed in part by page
hematopoietic lineages.23 Transplant of MDR1-transduced charge payment. This article must therefore be hereby marked
bone marrow cells confers resistance to TAXOL (Bristol-
‘‘advertisement’’ in accordance with 18 U.S.C. section 1734 solely to
Myers, Princeton, NJ) in irradiated W/WV mice.24 Demon- indicate this fact.
stration of the MDR1 transgene after serial transplantation q 1997 by The American Society of Hematology.
0006-4971/97/9002-0027$3.00/0through several generations of lethally irradiated hosts re-
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Wilmington, MA) as previously described.19 Donors in the first co- 7.5, 25 mmol/L EDTA [GIBCO Catalog #5577UA] with 0.75% 2-
mercaptoethanol and 0.5% NP-40) was added to each sample, vor-hort received 0.5 mg of recombinant murine stem cell factor (SCF;
Genetics Institute, Cambridge, MA) in 100 mL of Dulbecco’s Phos- texed for 10 seconds, and 25 mL of 2 mol/L sodium acetate (pH
4.5) was added. Then each tube received 350 mL of 50% phenol/phate-Buffered Saline (DPBS) by intraperitoneal (IP) injection 24
hours before collection of marrow. Cells were dispersed by pipetting 49% chloroform/1% isoamyl alcohol. Samples were vortexed for 10
seconds, ice chilled for 15 minutes, and microcentrifuged at 14,000with a 10-mL pipette, nucleated-cell counts obtained in a 19:1 dilu-
tion with crystal violet, centrifuged at 1,200 rpm for 10 minutes, and rpm for 2 minutes. The RNA was precipitated with isopropanol for
4 hours at 0207C, microcentrifuged at 14,000 rpm for 15 minutes,resuspended in DPBS (GIBCO, Grand Island, NY) to the appropriate
concentration. drained, and dried in a Speed Vac Evaporator (Savant Instruments
Inc, Holbrook, NY). Each pellet was resuspended in 200 mL of TE-MDR18.1 and N2-5 producer cell line. The cell line MDR18.1
produces the human MDR1 cDNA incorporated into an ecotropic NaCl (0.2 mol/L NaCl, 10 mmol/L Tris, 1 mmol/L EDTA, pH 7.2)
then precipitated in 800 mL of ethanol for at least 4 hours at 0207C.retroviral vector driven by the Harvey murine sarcoma virus long
terminal repeats,24,27 and the N2-5 cell line produces vector that RNA samples were pelleted at 14,000 rpm for 15 minutes, dried,
and then resuspended in 44 mL of sterile pure water (GIBCO) forcontains the Neomycin resistance gene (both obtained from David
Bodine, National Institutes of Health, Bethesda, MD). The MDR18.1 use.
The reverse transcriptase (RT) reaction was performed using 10and N2-5 cell lines were maintained at 377C 5% CO2 in growth
medium: Dulbecco’s modified Eagle’s medium (DMEM) low glu- mL of the colony RNA added to 14.5 mL of PCR-grade water, 3.5
mL of 10 U/mL RNasin (Promega, Madison, WI), and 2 mL of 10cose (GIBCO), 4 mmol/L glutamine (GIBCO), penicillin-streptomy-
cin (GIBCO), and 15% heat-inactivated newborn (less than 10 days) nmol/L random primers (GIBCO). After heating at 707C for 5 min-
utes, samples were ice chilled and to each was added 3.5 mL ofbovine serum (GIBCO).
Incubations (prestimulation and transduction). Bone marrow RNasin at 10 U/mL, 13 mL of 10X SSRT buffer (GIBCO), 17.5 mL
of 2 mmol/L dNTPs, and 1 mL of SSRTII RT (GIBCO). Samplescells were cultured at 1 1 106/mL in infection medium: DMEM
low glucose (GIBCO), 4 mmol/L glutamine (GIBCO), penicillin- were heated to 427C for 60 minutes, heated to 707C for 5 minutes,
and then either stored at 0207C or processed immediately in thestreptomycin (GIBCO), and 15% heat-inactivated fetal bovine serum
(Hyclone, Logan, UT) in Corning (Corning Inc, Corning, NY) sus- PCR reaction.
The PCR amplification reaction of the cDNA was performed onpension dishes (#25070-100). The 48-hour prestimulation was done
in medium alone or in the presence of a cytokine cocktail, which one third of each RT reaction (20 mL), allowing for sufficient tem-
plate to run duplicate samples and a control, usually a ’’no-primer‘‘contained 50 U/mL of interleukin-3 (IL-3), 50 U/mL IL-6, 50 ng/
mL recombinant human IL-11 (Genetics Institute), and 50 ng/mL reaction, for each colony. The modified ‘‘hot-start’’ PCR reactions
contained template and primer in the bottom layer, a layer of paraffinrecombinant murine SCF. Cells were harvested and resuspended in
a small volume of DPBS. Cells were cocultured with retroviral wax (Wax Gem 100, Perkin Elmer-Cetus, Norwalk, CT), and the
reaction mix containing buffer, nucleotides, and enzyme on the top.producer cells for 24 hours in the same medium and cytokine mixture
as the prestimulation at the same concentration (1 1 106/mL). Poly- Primers were used at a final concentration of 1 mmol/L and final
reaction conditions were 50 mmol/L KCl; 10 mmol/L Tris-HCl pHbrene (Hexadimethrine Bromide from Sigma, St Louis, MO) was
added to the retroviral cocultures at a final concentration of 6 mg/ 8.3; 3.25 mmol/L MgCl2; 0.2 mmol/L each dATP, dCTP, dGTP,
and dTTP; AmpliTAQ TAQ polymerase (Perkin Elmer), and 4 mCimL.
HPP-CFC assay. Bone marrow cells (control or transduced) 32 PdCTP (NEG-O37Z, NEN; DuPont, Wilmington, DE). PCR used
35 cycles of 947C for 1 minute, 557C for 1 minute, and 727C for 2were plated in the HPP-CFC assay as previously described.28,29
Briefly, for each 35-mm dish 25,000 or 50,000 cells are plated into minutes. Primers used for PCR24: MDR (upstream) 5*-GCC CAC
ATC ATC ATG ATC-3*; MDR (downstream) 5*-GTC TCC TACthe top agar layer (0.5 mL) over a bottom feeder layer of agar,
medium, and cytokines (1.35 mL). The cytokine mixture used for TTT AGT GCT-3*. For analysis, samples were resolved on a 5%
acrylamide gel and bands were measured by ultraviolet (UV)this in vitro hematopoietic progenitor colony assay is given as the
concentration in the underlayer, and the final concentration for the shadow, then gels were dried onto 3MM Whatman paper (Whatman
International, Kent, UK) and exposed to radiography film.entire dish is listed in brackets after. The 6-factor plates contained
52,000 U [38,000 U] human colony-stimulating factor-1 (CSF-1; Transplant into nonmyeloablated hosts. Transduced male
BALB/c bone marrow cells were harvested after the retroviral incu-Cetus, Emeryville, CA), 26 ng [19 ng] murine granulocyte-macro-
phage colony-stimulating factor (GM-CSF; Amgen, Thousand Oaks, bation and washed in Hank’s buffered saline solution (HBSS;
GIBCO) three times, then resuspended into DPBS for injection viaCA), 52 ng [38 ng] human granulocyte colony-stimulating factor
(G-CSF; Amgen), 1,040 U [760 U] murine IL-3 (Collaborative, tail vein into normal female BALB/c mice; injection volumes ranged
from 0.3 mL to 0.62 mL/mouse. The animals that completed theBedford, MA), 2,600 U [1,900 U] human IL-1a (Hoffmann-
LaRoche, Nutley, NJ), and 1.04 mg [0.76 mg] murine SCF (R & D study were (cell dose per day on consecutive days is listed after
each): TX1 (20 1 106, 20 1 106), TX2 (12 1 106, 12 1 106, 12 1Systems, Minneapolis, MN); for the 7-Factor plates, 52 ng [38 ng]
of bovine basic FGF (Collaborative) was also included. The high– 106, 12 1 106, 12 1 106), TX5 (10 1 106, 20 1 106, 14 1 106),
TX6 (20 1 106, 15 1 106), and TX40 and TX60 (DPBS each dayCSF-1 plates each received only 200,000 U [146,000 U] of CSF-1.
Plates were incubated at 377C, high humidity, 5% oxygen, and 10% for 5 days, same volume as cell infusions). Mice were given 10 mg/
kg TAXOL (IP) at three times over a 14-month period. TAXOLCO2 for 7 to 14 days. The HPP-CFC was defined as a tight ball of
cells at 14 days of greater than 0.5 mm in diameter or a dense colony was supplied by Bristol Myers/Squibb (Princeton, NJ), and delivered
at 5 and a half months, 9 and a half months, and 13 months posttrans-greater than 1.0 mm in diameter.
Colony reverse transcriptase-polymerase chain reaction (RT- plant. Animals were sacrificed and analyzed 2 weeks after the last
TAXOL injection.PCR) assay. Individual, nonoverlapping HPP-CFC colonies were
picked from the agar using a solution of sterile water with 0.2 Analyses of transplant recipients. The DNA from tissues and
organs was analyzed by Southern blot for the presence of Y chromo-mg/mL brewers yeast tRNA (Boehringer Mannheim, Mannheim,
Germany). Colony RNA was prepared by a variation of the method some specific sequences as previously described.19 Briefly, DNA
was digested with Dra I restriction endonuclease, resolved on 0.8%of Witesell and Schook.30 Briefly, 200 mL of a guanidine isothiocya-
nate (GSCN) solution (4 mol/L GSCN, 50 mmol/L Tris-HCl pH agarose gel, transferred in 0.4Normal NaOH to ZetaProbe (Bio-Rad,
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Richmond, VA), and probed for male specific sequence with the 11, and SCF) or medium alone. Cells were harvested and
PY2 plasmid31; gel loading was corrected using an IL-3 cDNA probe plated in either 6- or 7-factor HPP-CFC agar or in agar with
that recognizes an autosomal single copy gene.32 Signal from South- high–CSF-1 alone. From the cells cultured in the presence
ern blots was quantified using Radioanalytic Phosphorimaging (Mo- of the 4-cytokine cocktail, we selected 48 colonies. From
lecular Dynamics, Sunnyvale, CA). Initially, the DNAs were also the cells cultured in the absence of the additional cytokines,
analyzed for the presence of the MDR1-containing proviral DNA
we selected 51 colonies. Cells were plated in either 6-factorby Southern blot; however, the analysis was extended to include (n  53 colonies selected), 7-factor (n  64 colonies se-a more sensitive PCR assay using MDR1-specific primers (listed
lected), or high–CSF-1 (n  81 colonies selected) agar bi-previously) and an internal reaction and copy number control for
layers for 7 or 14 days. All colonies combined (n  99)murine b-globin [bg1 (upstream) 5*-GAA GTT GGG TGC TTG
GAG AC-3*; bg2 (downstream) 5*-GAG ACT GCT CCC TAG AAT resulted in an 88% transduction rate as determined by 87 of
CG-3*]. Whole cell preps from bone marrow and peripheral blood 99 colonies scoring positive for mRNA transcript from the
were also assayed by fluorescent in situ hybridization (FISH) using MDR1 transgene. Figure 2 shows the colonies by transduc-
a digoxygenin-labeled murine Y chromosome painting probe devel- tion group (in the presence or absence of added cytokines)
oped by U. Weier33 to selectively stain male bone marrow cells in and by plating groups. The transduction conditions did not
the transplant recipients.20 The presence of mRNA from the trans-
result in any significant difference in expression of theferred gene was evaluated using the same RT-PCR assay as de- MDR1 RNA by HPP-CFC colonies. Interestingly, the more
scribed for colony RNAs and 3 to 5 mg of total cellular RNA as
mature macrophage colonies on the high–CSF-1 plates weretemplate.
transduced at a lower efficiency (50%) as compared with
RESULTS the other transduction rates. Figure 3 summarizes the results
of each combination of transduction conditions and platingTo evaluate the percent of hematopoietic progenitor cells
type variables in a matrix.that were transduced effectively, we assayed for the expres-
Long-term engraftment of transduced progenitor cells intosion of the vector-transferred gene mRNA by RT-PCR from
normal hosts. For evaluation of engraftment of transducedindividual HPP-CFC colonies. The HPP-CFC is an in vitro
cells into the normal marrow microenvironment, the malesurrogate representing a multilineage hematopoietic progeni-
bone marrow cells were collected after transduction and in-tor/stem cell population that correlates with marrow re-
jected into normal nonmyeloablated female BALB/c hostsnewal.28,29 The HPP-CFC is the predominant cell, ap-
in a solution of DPBS. Mice were followed for 14 monthsproaching 100%, in certain ’’purified‘‘ stem cell populations
posttransplant by PCR of peripheral blood before and afterincluding the Hoechstlow Rhodaminelow lineage negative
each of the three TAXOL (10 mg/kg IP) injections, usingcells34 indicating that it is an in vitro surrogate for an early
MDR-specific primers. At each time point, all PCR analyseshematopoietic progenitor cell population. We have chosen
of peripheral blood samples were negative for MDR1 provi-to use the HPP-CFC assay, which represents an early progen-
ral sequences. At 14 months, 2 weeks after the third Taxolitor and which lends itself easily to colony RT-PCR analysis.
injection, host tissues were harvested and analyzed for bothThe HPP-CFC plating assay routinely includes six cyto-
Y-specific sequence and presence of the MDR provirus.kines (SCF, CSF-1, IL-1a , IL-3, G-CSF, and GM-CSF),
Analysis of bone marrow by FISH, using a male-specificand often basic FGF is added as well. Transduction of these
probe showed donor (ie, male) engraftment of the ex vivoprogenitors was determined by RT-PCR of individual colo-
manipulated marrow. The engraftment as determined by Y-nies to detect RNA from the transferred human MDR1 gene.
chromosome FISH shows engraftment levels between 8.9%Figure 1A shows examples of RT-PCR using MDR1 primers
and 13.4%. Slides were visually scored by three differentand RNA from HPP-CFC colonies. The cDNA from each
investigators and then averaged. Southern blot with phos-colony RT reaction is split into thirds, allowing for one
phorimage image analysis, resulted in calculated engraftmentcontrol reaction and duplicate analytical reactions. The colo-
values that were close to, but not identical to those obtainednies selected for analysis had opaque centers 1.0 to 2.0 mm in
by FISH: TX1 9.1%, TX2 7.0%, TX5 6.5%, TX6 7.1%, anddiameter. Additionally, a group of differentiated macrophage
TX40 and TX60 0%. Results are summarized in Table 1.colonies, grown in serum plus CSF-1, was screened and 50%
Engraftment in host splenic tissues from the same mice whenshowed expression of the MDR1 mRNA (Figs 2 and 3). The
determined by Southern blot was lower than in bone marrow:primers used are located upstream of a cryptic splice site
TX1 4.2%, TX2 0.6%, TX5 0.7%, and TX6 2.9%.in the MDR1 cDNA, thereby avoiding detection problems
PCR amplification was used to detect the presence ofassociated with the shortened mRNA that is sometimes gen-
MDR1 proviral DNA; this showed no detectable MDR1erated (D. Bodine, personal communication); in our hands
DNA in the peripheral blood taken before and after eachthis is not a problem as we get mRNA and protein expression
Taxol challenge. Additionally, there was no MDR1 DNAfrom the transgene. The routine positive and negative con-
detected in the bone marrow or spleen tissues harvested attrols that are needed for this assay are shown in Fig 1B.
14 months (Fig 4). Using RT-PCR to detect expression ofThe colony RT-PCR assay reproducibly detects the RNA
mRNA we did detect the MDR1 mRNA in bone marrow,transcript from the human MDR1 cDNA. Controls show no
although at very low levels as shown in Fig 5. From a dilu-signal from the possible sources of background, eg, mouse
tion curve prepared with MDR-transduced cells mixed withRNAs, tRNA carrier, and agar from between colonies.
noninfected cells, we estimate the number of cells producingWe analyzed 99 bone marrow HPP-CFC colonies from
MDR transcript to be between 1 in 10,000 and 1 in 100,000.cells transduced using the MDR18.1 retroviral producer line
in the presence of the four cytokine cocktail (IL-3, IL-6, IL- We conclude that our low expression of the transgene was
AID Blood 0019 / 5h39$$$361 06-12-97 00:41:13 blda WBS: Blood
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Fig 1. (A) RT-PCR detection of MDR1 expression by multifactor HPP-CFC. Single murine HPP-CFC colonies were picked and assayed for
expression of the transferred human MDR1 gene using the RT-PCR assay as described in Materials and Methods. The first set of three lanes
is from a 6-factor HPP-CFC (HPP#3) transduced with the MDR1 vector. This colony, as well as HPP#2, HPP#1, HPP#6, and HPP#4, all contain
the RT-PCR fragment corresponding to the mRNA from the transferred human MDR1 vector sequence. Each lane represents RNA equivalent
to 1/12 of a colony. Samples are run in duplicate with a no-primer (no 17) control. No-template negative control reactions are interspersed
among the assay samples. The last sets are NIH3T3 RNA (negative control, murine cell line), MDR18.1 RNA (positive control, MDR1 retroviral
producer line), and the tRNA/agar control for background (negative control for nonspecific signals and the carrier in the RNA isolation protocol).
(B) Colony RT-PCR assay controls. This panel shows the results of the control templates routinely run during the RT-PCR assay for MDR1
expression. Duplicate control templates are amplified concurrently with test samples using the same reagents and conditions; a no-primer
(no 17) control is also included for each. Control templates (from left to right) are (1) tRNA carrier, which is present in the RNA extractions:
This gives no RT-PCR background when SSRTII is used for reverse transcription; (2) agar from between colonies: Neither the agar nor any
extraneous material from the transduction or plating generates RT-PCR background; (3) MDR18.1 RNA from the producer cell line: 1 mg of
total cellular RNA in the RT step is included as a positive control; (4) NIH3T3 cell line RNA (or murine bone marrow RNA): 1 mg of total cellular
RNA in the RT step is included as a negative control (this is done to detect any cross reaction with any of the MDR isoforms present in mice);
(5) No-template reaction: This is a standard PCR control for each set of primers used; and (6) a nontransduced multifactor murine HPP-CFC
colony: This is processed identically to the experimental samples so that each lane represents 1/12 of a colony.
not a result of gene ‘‘shut-off’’ because the proviral DNA ered human MDR1 gene. In excess of 88% of HPP-CFC pro-
duce mRNA for the transgene. This colony assay reflects awas not detected. Rather the transgene is present and ex-
primitive pluripotential population of hematopoietic cells, whichpressed in only a small number of engrafted donor cells.
correlates with host marrow repopulation,34 and we concludeAlthough this demonstration is not stringently quantitative,
that standard transduction procedures, which use ex vivo cultureit is an exciting confirmation that successfully transduced
and cytokines to facilitate retroviral integration, are successfulcells were engrafted in the normal host.
in transfecting this primitive cell population.
DISCUSSION While demonstration of effective gene transfer into the
target cell population is critical to applying this model, it isThese data show that the majority of murine hematopoietic
progenitor cells are transduced with the retroviral vector-deliv- even more important to show that the cells responsible for
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Fig 2. Hematopoietic progenitor expression of MDR1 in vitro. Hematopoietic progenitor colonies, HPP-CFC, from bone marrow transduced
with the MDR18.1 retroviral vector were analyzed for expression of the MDR1 RNA using the RT-PCR assay. From a group of 99 colonies, 48
were generated by bone marrow transduced in the presence of cytokines (IL-3, IL-6, IL-11, and SCF), and 51 were generated by bone marrow
transduced in the absence of cytokines. As shown in the graph on the left, both groups were efficiently transduced. The transduction in the
presence of cytokines (") results in 83% of colonies positive for MDR1, and transduction in the absence of added cytokines (Ï) results in 92%
of the colonies scoring positive. After transduction (" or Ï cytokines), bone marrow cells were plated in either the multifactor HPP-CFC assay
or in CSF-1 alone. Of the 99 colonies analyzed, 81 were generated from the HPP-CFC assay and 18 were generated from the CSF-1 platings;
these are compared in the graph on the right. Colonies from the multifactor HPP-CFC assay are multilineage and highly proliferative (Û1.0
mm in diameter); 96% of these were positive for expression of MDR1 RNA. The colonies grown in CSF-1 alone were predominantly macrophages,
and were seldom greater than 0.5 mm in diameter; 50% of these were positive for expression of the MDR1 RNA. When the results of both
transduction methods and both plating assays are combined, the overall transduction rate into hematopoietic progenitors is 88%.
The nonablated bone marrow microenvironment may con-long-term in vivo engraftment can be effectively transduced.
stitute a qualitatively different engraftment site than theThese data show that transduced hematopoietic cells express-
’’empty‘‘ or altered marrow resulting from chemotherapy oring the human MDR1 gene are capable of long-term en-
radiation. In an ablated marrow, repopulation is essentiallygraftment in a nonablated host marrow. This has exciting
oligoclonal, the result of expansion of a small subpopulationapplications for gene therapy of genetic disorders and dis-
of engrafted progenitors. The use of nonmyeloablated hostseases such as HIV that do not necessitate destruction of the
was initally reported by Brecher et al22 and has been subse-host bone marrow.
quently used to characterize the functional status of en-
grafting hematopoietic stem cells.19-21,35 Using this model,
donor progenitor cell engraftment has been reproducibly
shown to be truly competitive in this environment. Donor
Table 1. Engraftment of Male Donor Cells Into Female Hosts
Percent Male Chimerism in Bone Marrow
Animal Total Cells Injected Y Chromosome FISH Southern Blot PY2
TX1 40 1 106 8.9 9.1
TX2 60 1 106 9.8 7.0
TX5 44 1 106 9.7 6.5
TX6 35 1 106 13.4 7.1
Bone marrow from each transplant recipient was assayed for the
percent of donor cell composition. The experiment label for each
animal appears in the first column (TX1, TX2, TX5, TX6). The total
number of male bone marrow cells injected into each female is listedFig 3. MDR1-positive colonies from different transduction me-
in the second column. The donor engraftment value determined bydium and plating conditions. The transduction results from a group
counting individual cells from bone marrow smears are listed in col-of 99 hematopoietic colonies, previously described in Fig 2, is shown
umn three. A positive signal in the fluorescence in situ hybridizationhere in grid format. The colonies are divided into transduction condi-
tions, four cytokines or in medium alone, along the vertical axis. Cells (FISH) assay is produced with a Y-chromosome–specific painting
are then further divided, along the horizontal axis, into the colony probe. To determine the percent male, the number of cells positive
assay conditions in which they were grown, HPP-CFC (6 or 7 factor) by FISH was divided by the total number of cells in each sample.
and high–CSF-1. The number of colonies in each group appears in Total cell counts were obtained by staining nuclear chromatin of all
parentheses. The percent positive is listed in bold in each section. cells with 4,6-Diamidino-2-phenylindole (DAPI). Several entire fields
This illustrates the efficient transfer of the vector into the HPP-CFC
were counted for each group (136 to 480 cells/group) by three individ-regardless of transduction conditions or plating assay; colonies are
uals and the results were averaged. Bone marrow DNA from each83% to 97% positive. Interestingly, both transduction conditions re-
mouse was analyzed by Southern blot using the PY2 plasmid.29 Thesulted in lower transfer into the macrophage colonies; 45% were
resulting donor engraftment values for whole bone marrow DNA arepositive from the four cytokine transductions and 57% were positive
from the transduction in medium alone. presented in column four.
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active cell cycle transit by these HPP-CFC forming cells.35
This entry into cell cycle by bone marrow progenitors results
in impaired long-term in vivo engraftment in nonmye-
loablated hosts regardless of whether cell-cycle progression
is induced by ex vivo culture in cytokines or by pretreatment
of donors with drugs such as 5-Fluorouracil.20,35 A competi-
tive engraftment model using irradiated murine hosts re-
sulted in loss of repopulation potential of the cycling cells
from cytokine-stimulated cultures after a few hours,44 thus
showing defective long-term engraftment in the ablated mar-
Fig 4. Analysis of host bone marrow DNAs for vector DNA. Bone
row as well. Taken together, these data show a strong corre-marrow DNA from transplant recipients and controls was analyzed
lation between active cell-cycle progression and loss of en-by PCR for the presence of the MDR18.1 vector DNA. For each reac-
tion, 250 ng of template DNA was amplified with the human MDR1 graftment potential.
primers and the murine b-globin primers using the same PCR reac- The engraftment defect correlated with the transduction
tion conditions as the MDR1 colony RT-PCR assay. The murine b- procedures is not limited to murine bone marrow transduced
globin serves as an internal standard for copy number and quality of
with the human MDR1 vector, MDR18.1. In additional stud-template. The MDR1 fragment is the upper band, and the b-globin
ies (data not shown), BALB/c mice that received bone mar-is 100 bases shorter and runs below the MDR1. This assay is capable
of detecting 1 copy of the transgene per haploid genome in Û1% of row transduced with the neomycin resistance gene, retroviral
the cells as determined by a standard dilution curve. None of the vector N2-5, also showed no detectable transfer of the
transplant recipients showed detectable amounts of MDR1 DNA us-
transgene by standard Southern blot.ing this assay. The templates assayed are (from left to right) two
Engraftment of murine bone marrow progenitors trans-no-template negative control reactions; NIH3T3 (murine cell line; neg-
ative control for human MDR1 gene); MDR18.1 (the retroviral produc- duced with a human MDR1 may also be influenced by host
ing murine cell line; positive control, producer line contains the provi- immunity. Although cell cycle considerations are compel-
ral genome); male murine spleen DNA (negative control); TX40 and ling, it is important to note that in a nonmyeloablated host,
TX60 bone marrow DNAs (negative control; these mice received no
the immune system may affect the selection of engraftingMDR-transduced cells, only phosphate-buffered saline); and TX1,
cells. In additional studies, sera from MDR1 transplant recip-TX2, TX5, TX6 bone marrow DNAs (transplant recipients).
ients showed no specific detectable response to cells express-
ing human MDR1 on their surface when assayed by fluores-
cence-activated cell sorting (data not shown). Additionally,cells labeled with PKH20 show superior engraftment in the
the response of splenic T-cells from the MDR1 transplantnormal host marrow, indicating that the nonmyeloablated
recipients to stimulation by a crude extract of MDR18.1 cellsmarrow microenvironment may even have advantages over
did not exceed the standard stimulation index (proliferationthe ablated host marrow.36
score divided by control score) significance value of 2.000The donor cell engraftment levels are in an acceptable
(data not shown). This lack of detectable immune systemrange for use in gene transfer procedures in nonablated hosts
recognition or response to human MDR1 indicates that fail-(8% to 10%). The number of progenitor cells that are trans-
ure of MDR1 transduced marrow to engraft in the nonablatedduced with the MDR1 gene is also within a range that would
host is probably not related to host immunity.facilitate efficient gene transfer, as shown by the high rate
Cytokine-stimulated proliferation is implicated as theof HPP-CFC scoring positive for MDR1 mRNA. However,
the number of effectively transduced progenitor cells that
engrafted is quite low. These data suggest that the majority
of progenitor cells that integrated the MDR1 gene failed to
engraft and that, of the cells that did engraft, only a small
fraction had integrated the transgene. Thus, we propose that
exposing the donor bone marrow to the retroviral transduc-
tion procedure impairs engraftment of transduced hemato-
poietic progenitors in the nonablated host.
To facilitate retroviral gene insertion, hematopoietic target
cells are frequently stimulated to proliferate in vitro with
cytokines. Cytokine stimulation induces the cell cycle transit
necessary for successful proviral integration into the geno-
Fig 5. RT-PCR detection of MDR1 in transplant recipient bone mar-mic DNA of the most primitive cells that are quiescent, or
row. RNA was harvested from bone marrows of the transplantedin G0 phase of the cell cycle.37-43 This procedure is intended mice at 14 months. Each RT reaction with 3 mg of total cellular RNA
to induce proliferation of early hematopoietic progenitor was split into three PCR reactions, these included two parallel analyt-
cells without inducing significant differentiation. The pro- ical reactions and a no primer (no 17) negative control. PCR conditions
were as described for colony RT-PCR. As shown in this autoradio-genitor population assayed by HPP-CFC colony formation
gram, there is low, but detectable, MDR transcript in each of the fouris an early multilineage hematopoietic cell that is quiescent
transplant recipient mice. Controls include female and male murine
and is stimulated to proliferate in vitro when plated in the spleen RNA from nontransplanted mice, murine bone marrow RNA
agar medium and cytokines. Recent data from our group from nontransplanted mice as negative controls, and RNA from the
MDR18.1 producer line as positive control.have shown that culture in cytokines results in the entry into
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mechanism that induces a functional change in the progenitor short viral incubation times without cytokines have achieved
expression of the transgene in children.45 Although this in-cells that is related in some way to their cell-cycle status.
This cell cycle related engraftment defect has been shown cluded introduction into an ablated marrow, it does suggest
that in vitro incubation with cytokines before stem cell trans-in nonablated hosts, as well as irradiated hosts.20,35,44 Interest-
ingly, in these studies that used the cytokine incubation to plant may be unnecessary.
This report establishes the transfer of the human MDR1facilitate retroviral integration, we achieved superior levels
of engraftment to those reported previously by Peters et gene into the nonmyeloablated murine host. Whereas the
demonstration of gene transfer in this model has excitingal.35,44 The retroviral transduction begins with the same cyto-
kine incubation but is then followed by a 24-hour coculture implications for gene therapy, the importance of maintaining
engraftment potential is strongly emphasized. These studieswith the retroviral producer cell line that is of murine fibro-
blast origin. We speculate that this might offer the progenitor show that stimulation of cell proliferation as a means to
facilitate retroviral vector integration results in an en-cells a needed cellular factor (conditioned medium) or sim-
ply be the result of cell-cell contact. It is an exciting possibil- graftment defect that corresponds to the induction of cell
cycle transit. We conclude that this gene-delivery system isity for providing an atmosphere that either maintains or even
reestablishes engrafting potential. To this end, many gene capable of transducing hematopoietic stem/progenitor cells,
but that a relatively small fraction of these cells are capabletransfer protocols are investigating the use of autologous
stromal components during ex vivo gene transfer. Transfer of engrafting and contributing to the hematopoietic system
of a nonmyeloablated host under the conditions of theseinto a nonmyeloablated canine host was achieved with trans-
duced long-term bone marrow cultures; the transduction of experiments. Maintaining the engraftment potential, either
by culture in a suitable microenvironment or by reversingcells cultured on autologous stroma resulted in retention of
engraftment ability.9 This manner of transduction, along with the loss of engraftment potential, will be an important step
in applications of hematopoietic stem cell transplantationother approaches, may be critical to maximizing the number
of long-term progenitors that retain engraftment potential and gene transfer.
while being effectively transduced.
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